Last reviewed · How we verify
DEB-TACE plus PD-1 inhibitor
DEB-TACE delivers chemotherapy directly to liver tumors via embolic beads while a PD-1 inhibitor simultaneously unleashes anti-tumor immune responses.
DEB-TACE delivers chemotherapy directly to liver tumors via embolic beads while a PD-1 inhibitor simultaneously unleashes anti-tumor immune responses. Used for Hepatocellular carcinoma (HCC), unresectable or advanced stage.
At a glance
| Generic name | DEB-TACE plus PD-1 inhibitor |
|---|---|
| Sponsor | Guangxi Medical University |
| Drug class | Combination therapy: locoregional chemotherapy + immune checkpoint inhibitor |
| Target | PD-1 (programmed death receptor 1) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
DEB-TACE (drug-eluting bead transarterial chemoembolization) is a locoregional therapy that combines chemotherapy-loaded beads with vascular embolization to target hepatocellular carcinoma. The addition of a PD-1 inhibitor blocks the PD-1/PD-L1 checkpoint, enhancing T-cell activation and anti-tumor immunity. This combination aims to synergize local tumor destruction with systemic immune activation.
Approved indications
- Hepatocellular carcinoma (HCC), unresectable or advanced stage
Common side effects
- Post-embolization syndrome (fever, pain, nausea)
- Immune-related adverse events (fatigue, rash, hepatotoxicity)
- Elevated liver enzymes
- Thrombocytopenia
Key clinical trials
- DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DEB-TACE plus PD-1 inhibitor CI brief — competitive landscape report
- DEB-TACE plus PD-1 inhibitor updates RSS · CI watch RSS
- Guangxi Medical University portfolio CI